Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Yahoo! Finance
R&D Expenses : Decreased to $17.2 million in 2023 from $49.3 million in 2022, reflecting completion of ENHANCE program activities. SG&A Expenses : Rose to $50.4 million in 2023 from $26.6 million in 2022, due to commercial and IT infrastructure build-out. Net Loss : Decreased to $54.4 million in 2023 from $68.7 million in 2022, indicating a reduction in total operating expenses. Debt Financing : Secured a $400 million debt facility to support growth and potential commercialization of ensifentrine. Warning! GuruFocus has detected 5 Warning Signs with GSBD. On February 29, 2024, Verona Pharma PLC ( NASDAQ:VRNA ) released its 8-K filing , announcing its financial results for the fourth quarter and full year ended December 31, 2023, and providing a corporate update. The clinical-stage biopharmaceutical company, which focuses on developing therapies for respiratory diseases, is on the cusp of a transformational period with the potential approval and commercial launch of its lead
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 [Yahoo! Finance]Yahoo! Finance
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024GlobeNewswire
- Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswire
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market ResearchPR Newswire
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market ResearchPR Newswire
VRNA
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- VRNA's page on the SEC website